Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

131I-rituximab: relationship between immunoreactivity and specific activity.

Andreas O Schaffland1, Franz Buchegger, Marek Kosinski

  • 1Division of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|October 9, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The contest between internal and external-beam dosimetry: The Zeno's paradox of Achilles and the tortoise.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2023
Same author

Endorsement of International Consensus Radiochemistry Nomenclature Guidelines.

European journal of hybrid imaging·2021
Same author

10 years of EJNMMI Research: an overview.

EJNMMI research·2021
Same author

Endorsement of International Consensus Radiochemistry Nomenclature Guidelines.

EJNMMI radiopharmacy and chemistry·2019
Same author

Endorsement of International Consensus Radiochemistry Nomenclature Guidelines.

European journal of nuclear medicine and molecular imaging·2019
Same author

Endorsement of International Consensus Radiochemistry Nomenclature Guidelines.

EJNMMI research·2019

Optimizing radioimmunotherapy for lymphoma, researchers found that labeling rituximab with a lower specific activity of iodine-131 (131I) preserved its immunoreactivity. This approach also reduced the number of polyiodinated antibodies, crucial for effective treatment.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Immunology

Background:

  • Radioimmunotherapy (RIT) is a promising treatment for lymphoma.
  • Optimizing the radiolabeling of therapeutic antibodies like rituximab is critical for RIT efficacy.
  • Specific activity and immunoreactivity of radiolabeled antibodies directly impact treatment outcomes.

Purpose of the Study:

  • To investigate the impact of different specific activities of iodine-131 (131I) on rituximab labeling for lymphoma radioimmunotherapy.
  • To comparatively measure the immunoreactivity of rituximab labeled at two distinct specific activities.
  • To develop a statistical model predicting the degree of iodination and its correlation with immunoreactivity.

Main Methods:

  • Rituximab was labeled with 131I at two different specific activities (labelings A and B) using chloramine T.

Related Experiment Videos

  • Labeling efficacy and immunoreactivity were assessed using Raji and Daudi lymphoma cells.
  • Anion-exchange chromatography was used for purification.
  • Statistical analysis, including Gaussian distribution and Newton's binomial, predicted mono- and polyiodinated antibody frequencies.

    • Main Results:

    • All labelings achieved >98.4% radiochemical purity.
    • Labeling B (0.17 iodine atoms/antibody) exhibited significantly higher immunoreactivity (>28% increase) compared to labeling A (0.87 iodine atoms/antibody).
    • Predictive analysis indicated 15.4% polyiodinated antibodies for labeling B versus 57.3% for labeling A.

    Conclusions:

    • Lower specific activity of 131I-rituximab preserves high immunoreactivity.
    • Reduced polyiodination at lower specific activity is associated with better antibody function.
    • These findings support optimizing labeling conditions for enhanced lymphoma radioimmunotherapy.